Des-acyl ghrelin and analogs as cancer therapies
AssigneeCornell University
InventorKristy A. BROWN
Life of this patent
Estimating the term…
Abstract
The present technology relates to methods for treating, preventing, and/or ameliorating cancer comprising administering a therapeutically effective amount of ghrelin, des-acyl ghrelin, or an analog thereof (e.g, the cyclic peptide analog AZP531) to a subject in need thereof. Kits for use in practicing the methods are also provided.
Claims28
A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of ghrelin, des-acyl ghrelin, or an analog thereof, wherein the cancer does not comprise a mutation in BRAF, HRAS, and KRAS, and optionally wherein the effective amount of ghrelin, des-acyl ghrelin, or the analog is about 10-100 pM.
(canceled)
(canceled)
(canceled)
(canceled)
A method for monitoring the therapeutic efficacy of a pharmaceutical composition in a subject diagnosed with or suffering from cancer comprising:
- detecting phosphorylation levels of one or more signaling proteins selected from the group consisting of ERK1/2, p90RSK, Akt, and p70S6K in a test sample obtained from the subject after the subject has been administered the pharmaceutical composition;
- and
- determining that the pharmaceutical composition is effective when the phosphorylation levels of the one or more signaling proteins in the test sample are reduced compared to that observed in a control sample obtained from the subject prior to administration of the pharmaceutical composition, or
- detecting expression levels of one or more genes selected from the group consisting of cMYC, CDK4/cyclin D3, pRB (Ser 795) and BCL2 in a test sample obtained from the subject after the subject has been administered the pharmaceutical composition;
- and
- determining that the pharmaceutical composition is effective when the expression levels of the one or more genes in the test sample are reduced compared to that observed in a control sample obtained from the subject prior to administration of the pharmaceutical composition,
- wherein the pharmaceutical composition comprises ghrelin, des-acyl ghrelin, or an analog thereof, and wherein the cancer does not comprise a mutation in BRAF, HRAS, and KRAS.
(canceled)
A method for reducing chemotherapy-induced side effects in a subject diagnosed with or suffering from cancer comprising:
- administering to the subject an effective amount of ghrelin, des-acyl ghrelin, or an analog thereof, and an effective amount of a chemotherapeutic agent, wherein the cancer does not comprise a mutation in BRAF, HRAS, and KRAS, optionally wherein the chemotherapy-induced side effects comprise muscle cell death or cardiotoxicity.
(canceled)
(canceled)
A kit comprising a composition including ghrelin, des-acyl ghrelin, or an analog thereof and instructions for using the composition to treat a cancer that does not comprise a mutation in BRAF, HRAS, and KRAS, optionally wherein the analog is a cyclic peptide comprising the amino acid sequence SPEHQRVQ (SEQ ID NO:
- 4).
(canceled)
Dependencies are inferred from the claim text.